Antiangiogenic therapy for patients with choroidal neovascularization in the facilities of Viveya Consultive and Diagnostic Center
The development of choroidal neovascularization (CNV) is one of the unfavorable variants of the course of such retinal diseases as age-related macular degeneration (AMD), post-thrombotic retinopathy, complicated myopia, diabetic retinopathy and is the cause of irreversible vision loss in people of the older age group. Over the past decade, with the introduction of anti-VEGF-npenapates (drugs that inhibit neoangiogenesis), a revolution has occurred in the treatment of this pathology, which made it possible not only to preserve, but also to improve the vision of patients. Since 2011, the widespread use of intravitreal injections of the drug "Ranibizumab" has begun in Russia, and since 2016, "Aflibercept", but one of the lowest rates of use of this type of treatment remains in Russia. Since May 2020, the treatment of patients with CNV by intravitreal administration of the drug Aflibercept (Eilea) has been started at the CDC "Viveya". The presence of the Vivea-based Outpatient Surgery Center allows these manipulations to be carried out on an outpatient basis. Patient management, preoperative general clinical examination in the multidisciplinary medical center "Viveya" allows to reduce the time from diagnosis to the start of treatment, reduce the number of visits, and improve compliance